Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
© 2023, The American College of Clinical Pharmacology..
With the promise of a potentially single-dose curative regimen, CAR-T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR-T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR-T cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long-lasting cell persistence and a favorable exposure-response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose-limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR-T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR-T cell therapy in solid tumor space.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacology - 64(2024), 3 vom: 31. März, Seite 362-370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Di [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcph.2346 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36191766X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36191766X | ||
| 003 | DE-627 | ||
| 005 | 20240422231934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcph.2346 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM36191766X | ||
| 035 | |a (NLM)37694295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Di |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023, The American College of Clinical Pharmacology. | ||
| 520 | |a With the promise of a potentially single-dose curative regimen, CAR-T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR-T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR-T cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long-lasting cell persistence and a favorable exposure-response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose-limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR-T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR-T cell therapy in solid tumor space | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CAR-T cell therapy | |
| 650 | 4 | |a DLL3 | |
| 650 | 4 | |a cellular kinetics | |
| 650 | 4 | |a small cell lung cancer | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a DLL3 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Intracellular Signaling Peptides and Proteins |2 NLM | |
| 700 | 1 | |a Byers, Lauren A |e verfasserin |4 aut | |
| 700 | 1 | |a Sable, Beate |e verfasserin |4 aut | |
| 700 | 1 | |a Smit, Marie-Anne Damiette |e verfasserin |4 aut | |
| 700 | 1 | |a Sadraei, Nooshin Hashemi |e verfasserin |4 aut | |
| 700 | 1 | |a Dutta, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Upreti, Vijay V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacology |d 1973 |g 64(2024), 3 vom: 31. März, Seite 362-370 |w (DE-627)NLM000005576 |x 1552-4604 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g number:3 |g day:31 |g month:03 |g pages:362-370 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcph.2346 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |e 3 |b 31 |c 03 |h 362-370 | ||